Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ACP3 | P15309 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584516 | 0.85 | TSHR (0.54) | TSHRSMN1; SMN2MEN1HTTKMT2A | |
| SCHEMBL6449834 | 0.84 | MME (0.58) | TSHRMMEACENPC1RAB9A | |
| SCHEMBL27453354 | 0.82 | SLC1A3 (0.51) | TSHRSMN1; SMN2MEN1HTTKMT2A | |
| SCHEMBL8644896 | 0.81 | MME (0.51) | MME | |
| SCHEMBL4556535 | 0.81 | PTGS2 (0.50) | MMESMN1; SMN2NPC1RAB9A | |
| SCHEMBL585397 | 0.79 | MME (0.56) | MMEMEN1KMT2AACE | |
| SCHEMBL20291832 | 0.79 | MME (0.56) | MMEMEN1KMT2AACE | |
| SCHEMBL16201777 | 0.78 | CNR2 (0.46) | TSHRMMESMN1; SMN2MEN1HTT | |
| SCHEMBL23699060 | 0.78 | MME (0.51) | MME | |
| SCHEMBL9196225 | 0.78 | HTT (0.55) | MMEHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143968-A1 | PENICILLIN-G ACYLASES | CODEXIS, INC. (US) | 2010-06-10 | — | — | US | claimed |
| WO-2010054319-A2 | PENICILLIN-G ACYLASES | CODEXIS, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| US-8569013-B2 | Penicillin-G acylases | CODEXIS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120270282-A1 | PENICILLIN-G ACYLASES | CODEXIS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8247192-B2 | Penicillin-G acylases | CODEXIS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20100143968-A1 | PENICILLIN-G ACYLASES | CODEXIS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2010054319-A2 | PENICILLIN-G ACYLASES | CODEXIS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270282-A1 | PENICILLIN-G ACYLASES | PGLS, PNP, NAAA | TSHR 4126/4885MME 1536/4885SMN1; SMN2 2589/4885 |
| US-20100143968-A1 | PENICILLIN-G ACYLASES | PGLS, PNP, NAAA | TSHR 4126/4885MME 1536/4885SMN1; SMN2 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.